Using P501s to Detect Prostate Cancer
Author Information
Author(s): Yin Ming, Dhir Rajiv, Parwani Anil V
Primary Institution: University of Pittsburgh Medical Center
Hypothesis
The study aims to evaluate the expression of P501s in metastatic prostatic adenocarcinoma and compare it with PSA.
Conclusion
P501s is a specific marker for prostatic cells and improves the detection of metastatic prostate cancer when used alongside PSA.
Supporting Evidence
- P501s was expressed in all benign glands and malignant acini.
- No staining was observed in non-prostatic tissues.
- Simultaneous stains with P501s and PSA improved detection rates.
Takeaway
P501s helps doctors find prostate cancer better, especially when PSA tests don't work well.
Methodology
Immunohistochemical stains with anti-P501s antibodies were performed on tissue microarray specimens from various prostate-related tissues.
Limitations
The study did not provide Gleason scores for the metastatic lesions, which may affect the interpretation of results.
Participant Demographics
The study included various prostate tissue types, including normal, benign, and malignant samples.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website